🎣 The Cast, Vol. 2:
Buying Execution, Not Just the Story: A Spec Play and a Release
Worksport ($WKSP)
Price (as of 7/2): $3.11
Market Cap: ~$15M
Why It Caught My Eye
Worksport is a U.S. based manufacturer of truck tonneau covers, operating in a category with both steady demand and expanding distribution channels. While the company flew under the radar for years, recent sales growth suggests a real inflection point may be underway.
The Meat
Worksport’s tonneau covers are sold through wholesalers, e-commerce, and most importantly a rapidly expanding dealer network.
Q1 2025 Revenue: $2.24M (+337% YoY)
Management says April and May revenue alone surpassed all of Q1, and they expect June to outpace May as a new national distributors ramps up.
The dealer count has exploded from 94 in Q4’24 to over 550 today, with two major distributors being onboarded this spring.
New & Upcoming Product Launches
Worksport isn’t getting comfortable, it’s launching new products aimed at broadening appeal and tapping into adjacent markets:
AL4 Hard Tonneau Cover (now in rollout)
SOLIS Solar Tonneau Cover + COR Portable Energy System (launching Fall 2025)
The SOLIS & COR brings exposure to the energy-tech space, creating potential for cross-sector revenue if execution is solid.
Why Is the Market Unimpressed?
Despite the operational momentum, the stock hasn’t moved in step. The share price remains subdued possibly due to:
Lack of institutional coverage
Cash burn concerns and thin liquidity
But if the company delivers even a fraction of what’s expected in H2, that could change.
Potential Catalysts
A large government sales order
Continued dealer expansion
Possible OEM or national retailer partnerships
Successful solar product launch in the fall
Rotten Risk
Execution risk on new product launches
Thin margins and limited cash runway
Still no mass-market validation for the energy line
Verdict: Taking a Bite (Speculative Buy)
The growth is real. The pipeline is strong. And the valuation? Still sitting near 1x run-rate revenue.
With multiple near-term catalysts and a product suite that’s finally gaining traction, I’ve initiated a small, speculative position.
What I’m Watching:
June/July revenue trends
Distributor and dealer order flow
COR/SOLIS launch adoption this fall
📌 It’s early, but this might be one of those micro-cap pivots that works.
Owlet Inc. ($OWLT)
Price (as of 7/2): $8.38
Market Cap: ~$141M
Why It Caught My Eye
Owlet makes smart infant health monitoring devices, including its flagship Smart Sock, which tracks a baby’s heart rate, oxygen levels, and sleep patterns. The company positions itself at the intersection of consumer tech, medtech, and parenting, with a mission to “modernize infant care.”
While it once traded as a post-SPAC high-flyer, Owlet was pummeled by regulatory setbacks and ongoing losses. But after a major 2023 reset including an FDA clearance, the company might be showing signs of life again.
The Hook and Sinker
Owlet is in the early innings of what it hopes is a credible turnaround:
In late 2023, Owlet received FDA clearance for the Dream Sock as a medical device—making it the first over-the-counter infant monitoring product cleared by the FDA.
Owlet is building out hospital partnerships to distribute its BabySat and Dream Sock to NICU discharges.
Owlet360, the in-app subscription service providing health insights, now has 48,000+ paying subscribers, creating high-margin, recurring revenue and expanding LTV.
Management is targeting full year 2025 positive adjusted EBITDA with $91 to $95 million in revenue.
Financials: Improvement
Q1 2025 Revenue: $21.1M (↑ 43.1% YoY)
Gross Margin: 53.7% (improved 930 bp YoY)
Net Income: $3.0M (Down .3M YoY)
Cash: ~$16.3M
These results reflect continued momentum post-FDA clearance, strong retail traction, and improved operating efficiency. The company remains profitable on a net income basis and maintains a modest cash cushion relative to its size. Burn appears under control — a major improvement from past quarters.
Potential Catalysts
New distribution in pediatric hospital channels
Owlet360 subscriber growth
International & retail scaling
User Experience a Bit Rotten
Despite the improving fundamentals, a deep dive into product reviews raised serious red flags:
Frequent false alarms, especially overnight
Connectivity issues with the app and sock pairing
Battery/reliability concerns after ~1 year
Subscription model backlash for locking key features
Customer support frustrations around warranty enforcement
In a product tied to infant health, even minor usability issues become major dealbreakers. The trust gap between the tech and its target audience is still too wide.
Verdict: Catch and Release
Owlet checks some of the boxes: FDA clearance, strong margins, and renewed retail momentum. But the real test is consumer trust, and that’s where it fails.
The Dream Sock’s poor user experience especially in a category as sensitive as infant safety makes this a product-driven story without a reliable product. Even with improving financials, the core offering doesn’t meet the bar for mass adoption.
📌 I’m tossing this one back into the water. Interesting setup, but not a catch I can hold onto with confidence.
💬 Have a stock you think deserves a cast? Leave a ticker in the comments or reply to this post.
📩 New to the series? Subscribe below to get the next edition of The Cast straight to your inbox.